What does Syntis Bio do?
Syntis Bio is a Boston-based clinical-stage biopharmaceutical company focused on developing oral therapies that leverage the small intestine's unique biology to provide effective treatment options for obesity, diabetes, rare genetic disorders, and other intestinal-related conditions. The company is advancing a pipeline that includes its lead obesity program, SYNT-101, and therapies targeting orphan metabolic diseases.
How much did they raise?
The company raised $38M in a Series A round led by Cerberus Ventures, with additional participation from Mansueto Investments, Woori Venture Partners, Apollo Labs, BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures, and Cerity Partners Ventures.
What are their plans for the money?
With the new funds, Syntis Bio plans to expand its operations and strengthen its research and development efforts, which could accelerate the advancement of its pipeline and enhance its capability to bring novel oral therapies to market.
What have they achieved so far?
Syntis Bio has already demonstrated progress by securing up to $5M in non-dilutive funding from the NIH through two Fast-Track SBIR awards, supporting the advancement of its SYNT™ platform.
